There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncternal Therapeutics (ONCT) and I-MAB (IMAB) with bullish sentiments.
Oncternal Therapeutics (ONCT)
Oncternal Therapeutics received a Buy rating and a $16.00 price target from Brookline Capital Markets analyst Kumaraguru Raja today. The company’s shares closed last Monday at $7.58.
According to TipRanks.com, Raja is a 4-star analyst with an average return of 19.7% and a 45.8% success rate. Raja covers the Healthcare sector, focusing on stocks such as Hepion Pharmaceuticals, Outlook Therapeutics, and CNS Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncternal Therapeutics with a $15.33 average price target.
See today’s analyst top recommended stocks >>
I-MAB (IMAB)
In a report released today, Kelly Shi from Jefferies maintained a Buy rating on I-MAB, with a price target of $75.00. The company’s shares closed last Monday at $44.38.
Shi has an average return of 414.1% when recommending I-MAB.
According to TipRanks.com, Shi is ranked #2093 out of 7406 analysts.
Currently, the analyst consensus on I-MAB is a Strong Buy with an average price target of $75.20, a 49.2% upside from current levels. In a report issued on March 15, Needham also initiated coverage with a Buy rating on the stock with a $75.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
